oleclumab,ceralasertib,durvalumab,olaparib,danvatirsen,trastuzumab deruxtecan,cediranib,vistusertib
merck,astrazeneca,daiichi sankyo
['hudson']
hudson #aacr23 shows increasing adherence to recommended survivorship care, from 20% to about 40% now. even though guidelines available since '03, still not implemented. focus on provider, next on the health system (insurance, affiliations, emrs)
Business development, marketing and sales professional in the life sciences, cancer diagnostics, and genomics fields. Blog: https://t.co/IeMzCogxlt. Opinions are my own.